🇺🇸 FDA

Intelligence Platform

Patents

Browse 50 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12421220

Bicyclic-substituted glutarimide cereblon binders

C4 THERAPEUTICS, INC. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12371442

Isoindolinone and indazole compounds for the degradation of EGFR

C4 THERAPEUTICS, INC. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12227504

Spirocyclic compounds

C4 THERAPEUTICS, INC. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180225

N/O-linked degrons and degronimers for protein degradation

C4 THERAPEUTICS, INC. · Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12157735

Compounds for targeted degradation of BRD9

C4 THERAPEUTICS, INC. · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091397

Dihydroquinolinones for medical treatment

C4 THERAPEUTICS, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12077498

C4-carboxylic acid-substituted tryptamine derivatives and methods of using

Enveric Biosciences Canada Inc. · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12076405

Heterocyclic degronimers for target protein degradation

C4 THERAPEUTICS, INC. · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12065404

C4-carboxylic acid-substituted tryptamine derivatives and methods of using

Enveric Biosciences Canada Inc. · Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12048747

Substituted piperidine Degronimers for Target Protein degradation

C4 THERAPEUTICS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12048749

C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

Revolution Medicines, Inc. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049464

Compounds for targeted degradation of BRD9

C4 THERAPEUTICS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12048748

Spirocyclic degronimers for target protein degradation

C4 THERAPEUTICS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12024509

Therapeutic compounds as inhibitors of the orexin-1 receptor

C4X Discovery Limited · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11992531

C3-carbon linked glutarimide degronimers for target protein degradation

C4 THERAPEUTICS, INC. · Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11945778

C4-carbonothioate-substituted tryptamine derivatives and methods of using

Enveric Biosciences Canada Inc. · Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845726

C4-carbonothioate-substituted tryptamine derivatives and methods of using

Enveric Biosciences Canada Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11802131

Glutarimides for medical treatment

C4 THERAPEUTICS, INC. · Granted Tue Oct 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11753398

Therapeutic compounds

C4X Discovery Limited · Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11753397

Cereblon binders for the degradation of ikaros

C4 THERAPEUTICS, INC. · Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11746087

C4-carboxylic acid-substituted tryptamine derivatives and methods of using

Enveric Biosciences Canada Inc. · Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11707447

C4-carbonothioate-substituted tryptamine derivatives and methods of using

Enveric Biosciences Canada Inc. · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11691972

Compounds for targeted degradation of BRD9

C4 THERAPEUTICS, INC. · Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11673902

Isoindolinone and indazole compounds for the degradation of EGFR

C4 THERAPEUTICS, INC. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted